Related Experiment Videos
Lack of p16/CDKN2 alterations in thyroid carcinomas
K Yane1, N Konishi, Y Kitahori
1Department of Otorhinolaryngology, Nara Medical University, Kashihara, Japan.
Cancer Letters
|March 19, 1996
Summary
Mutations in the p16/CDKN2 gene are not essential for thyroid cancer development. However, alterations in the p53 gene may contribute to the progression of differentiated thyroid tumors into undifferentiated carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Thyroid carcinomas are heterogeneous malignancies.
- Understanding the genetic alterations driving thyroid cancer progression is crucial for targeted therapies.
Purpose of the Study:
- To investigate mutations in the p16/CDKN2 and p53 tumor suppressor genes in various human thyroid carcinoma types.
- To determine the role of these genes in thyroid cancer development and progression.
Main Methods:
- Screening of p16/CDKN2 (exons 1-3) and p53 (exons 4-9) genes using single-strand conformation polymorphism (SSCP) analysis.
- Direct sequencing of PCR-amplified DNA from 21 papillary, 2 undifferentiated, 1 follicular, 1 medullary thyroid carcinomas, and 2 undifferentiated carcinoma cell lines.
Main Results:
- No mutations or homozygous deletions were found in the p16/CDKN2 gene in any samples.
- Point mutations in the p53 gene were identified in one undifferentiated carcinoma and both cell lines.
Conclusions:
- p16/CDKN2 gene alterations are not a prerequisite for thyroid malignant transformation.
- p53 gene mutations appear to be involved in the transition from differentiated to undifferentiated thyroid carcinoma.